when to stop glp 1 before pregnancy GLP-1 weight-loss drugs pose hidden risks for young women GLP-1 Medications and Pregnancy: When

and K.W.S

Study period 1/1/2021 to 10/1/2024 with follow-up possible through 7/1/2025 Study population: inclusion Patients with: PCOS (encounter or billing diagnosis with ICD-10-CM code E28.2) before exposure or within two years of drug trial start Evaluated sex of female or ambiguous Aged 18 to 50 at drug trial start No overlap in metformin and GLP-1 use At least one measurement within one year prior to trial start At least one measurement 9 to 15 months after trial start At least 70% of days covered by their exposure medication dispense Study population: exclusion Patients with: Evidence of pregnancy during baseline or outcome measurements Definitive pregnancy start date: Between 12 months before the first reading through the follow-up reading Definitive pregnancy end date, delivery, or if its ambiguous what point in the pregnancy the patient would be at (e.g

Store the medication properly and use a clean needle for each injection

Andrew has an MSci (Hons.) degree in medical and biological chemistry from the University of Nottingham, with his penultimate undergraduate year spent working with AstraZeneca in Sweden

There is early research on experimental GLP-1 patches for various conditionsusing advanced microneedle delivery systems, but these remain in preclinical stages

For these reasons, most medical guidelines recommend postponing pharmacological weight loss interventions until after breastfeeding concludes, unless maternal health risks make immediate intervention necessary and appropriate medical oversight is in place